Connected blood pressure monitoring during BTK inhibitor therapy
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study tests whether using a connected blood pressure monitor at home can help manage blood pressure in people starting a BTK inhibitor (a type of targeted therapy for blood cancers). Participation may help detect and manage high blood pressure early, which is a known side effect of these drugs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have a blood cancer such as chronic lymphocytic leukemia, follicular lymphoma, marginal zone lymphoma, lymphoplasmacytic lymphoma, Waldenström macroglobulinemia, or mantle cell lymphoma.
- You are about to start a BTK inhibitor (ibrutinib, acalabrutinib, or zanubrutinib) either as your first treatment or after a relapse.
- You have access to the internet and can use a connected blood pressure monitor.
- You are able to provide written informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well blood pressure is managed and whether heart problems can be prevented in people with certain blood cancers who are taking a type of targeted therapy called a BTKi. It aims to help you stay healthier during treatment.
This study looks at whether certain blood cancer treatments increase the risk of an irregular heartbeat called atrial fibrillation. It may help doctors understand which patients need closer heart monitoring.
This study looks at how health-related quality of life changes in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) when starting a new treatment. The goal is to better understand what affects well-being during therapy.
This observational study tracks how your heart rhythm (heartbeat pattern) changes while you take a BTK inhibitor or venetoclax. It may help doctors better understand heart rhythm risks in people receiving these cancer-related medicines.
This study watches for high blood pressure and irregular heartbeats in people with CLL who are starting a type of targeted therapy called a BTK inhibitor (acalabrutinib or zanubrutinib). Researchers will use a smartwatch and blood pressure cuff to monitor your heart health at home.
This study checks how often abnormal heart rhythms happen when you start a BTK inhibitor (used for certain blood cancers). It uses a small implanted heart monitor to record your rhythm continuously before and after starting the medication, so doctors can detect and manage problems early.
Hear when a new Waldenstrom Macroglobulinaemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.